NCT06491355View on ClinicalTrials.gov

First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2026

Conditions
Efficacy, SelfSafety IssuesColo-rectal Cancer
Interventions
DRUG

mfolfox6 and hlx04 regimen and Serplulimab

mfolfox6 and hlx04 regimen induction therapy followed by combined treatment with slulimumab in the experimental arm. In the active comparator. only with mfolfox6 and hlx04 regimen treatment.

DRUG

mfolfox6 and hlx04 regimen

In the active comparator. only with mfolfox6 and hlx04 regimen treatment.

Trial Locations (1)

310016

Sir Run Run Shao hospital, Hanzhou

All Listed Sponsors
lead

Sir Run Run Shaw Hospital

OTHER

NCT06491355 - First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter